The clinic owners publish this general guide to hip soreness

The ownership notice explains the clinic's business interest

The people behind the Phoenix-area QC Kinetix clinics publish this guide. The ownership notice below makes that business interest clear. It matters because the same people offer the care discussed here.

The guide isn't a diagnosis. It doesn't know where your soreness sits or which movement hurts. It can't test the hip or match an X-ray with the exam. A clinician who examines you can do those things.

One QC Kinetix option is platelet-rich plasma (PRP), a regenerative treatment made by drawing the patient's blood, spinning it into layers, and using the platelet-rich part as a shot after an exam.

The ownership notice tells you who may gain from the choice. The linked medical papers show what happened in groups of patients. The exam checks your sore hip. Each serves a separate purpose.

Use this guide to prepare a few direct questions. Ask which part of your hip may be sore. Ask which daily task may get easier. Get the cost and likely follow-up. Find out which choice follows if the first care doesn't help.

Research can't predict your result. A clinic answer shouldn't depend on a broad promise. It should name the care, the likely aim, and the limits.

Sources

1. A JBJS systematic review screened 420 papers on intra-articular cellular therapy for knee OA and focal cartilage defects and found only SIX at Level III evidence or higher (4 Level II, 2 Level III), covering 300 knees, with wide variation in cell source, cell characterisation, adjuvant therapy and outcome assessment - meaning no consensus exists on indications, cell sources, preparation or delivery. Two products called 'stem cell therapy' at two clinics may share almost nothing.

   Chahla J, et al. — Intra-Articular Cellular Therapy for Osteoarthritis and Focal Cartilage Defects of the Knee: A Systematic Review of the Literature and Study Quality Analysis.. The Journal of bone and joint surgery. American volume, 2016. DOI: 10.2106/JBJS.15.01495.

2. A Level-1a systematic review of 87 randomized PRP-for-knee-OA trials (7,925 patients, 8,118 knees) scored them against the 23-item MIBO reporting checklist. The overall MIBO score was 72%, 71% of studies scored below 80%, and reporting was worst on exactly the items that define the product: whole-blood characteristics (20%), platelet recovery rate (22%), PRP analysis (30%), PRP activation (47%). Adherence did not improve after MIBO was published. Much of the PRP literature does not say what was actually injected.

   Nakagawa HF, et al. — Systematic Review of Randomized Controlled Trials Evaluating the Use of Platelet-Rich Plasma for Knee Osteoarthritis: Adherence to Minimum Information for Studies Evaluating Biologics in Orthopaedics.. The American journal of sports medicine, 2025. DOI: 10.1177/03635465241249996.

3. A network meta-analysis restricted to LARGE intra-articular trials (57 RCTs, 22,795 participants, >=100 patients per group) found treatment effects were consistently larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had no effect on pain (SMD -0.04, 95% CI -0.19 to 0.11) with higher odds of dropouts due to adverse events (OR 2.01) and serious adverse events (OR 1.86) than placebo. Effects of 16 of 18 interventions were smaller than the MID.

   Pereira TV, et al. — Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.. Osteoarthritis and Cartilage, 2025. DOI: 10.1016/j.joca.2024.08.014.